Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy.

Published

Journal Article (Review)

There is no standard of care for older patients with newly diagnosed acute myeloid leukemia (AML) unfit for intensive therapy, and prognosis with currently recommended low-intensity therapies (decitabine, azacitidine, and low-dose cytarabine [LDAC]) remains poor. One promising strategy is to combine low-intensity treatments with novel agents. Gemtuzumab ozogamicin, tipifarnib, and barasertib have been investigated in phase 2/3 or 3 trials combined with LDAC, and phase 3 trials are currently investigating sapacitabine plus decitabine, and volasertib plus LDAC in AML. This review discusses current treatment recommendations and the development of combination therapies for older patients unfit for intensive therapy.

Full Text

Duke Authors

Cited Authors

  • Erba, HP

Published Date

  • February 2015

Published In

Volume / Issue

  • 39 / 2

Start / End Page

  • 183 - 191

PubMed ID

  • 25577399

Pubmed Central ID

  • 25577399

Electronic International Standard Serial Number (EISSN)

  • 1873-5835

Digital Object Identifier (DOI)

  • 10.1016/j.leukres.2014.11.027

Language

  • eng

Conference Location

  • England